Method of producing particles of microencapsulated antiseptic-stimulator dorogova (asd) fraction 2 in sodium alginate

FIELD: chemistry.

SUBSTANCE: invention provides a method of encapsulating antiseptic-stimulator Dorogova (ASD) fraction 2. The method is a physical-chemical non-solvent deposition method. When carrying out the method, the cladding of the microcapsules used is sodium alginate and the precipitation agent is carbon tetrachloride.

EFFECT: simple and faster process of producing microcapsules and higher mass output.

2 ex

 

The invention relates to the field of encapsulation.

Previously known methods for producing microcapsules.

In Pat. 2173140, IPC A61K 009/50, A61K 009/127 Russian Federation, published 10.09.2001, method for obtaining kremnijorganicheskih microcapsules using a rotary cavitation plants with high shear effort and powerful acoustic phenomena of sound and ultrasound range for dispersion.

The disadvantage of this method is the use of special equipment - rotary-cavity setup, which has the ultrasonic action that affects the formation of microcapsules and can cause adverse reactions due to the fact that ultrasound destructive effect on the polymers of protein nature, therefore the proposed method is applicable when working with polymers of synthetic origin

In Pat. 2359662, IPC A61K 009/56, A61J 003/07, B01J 013/02, A23L 001/00 published 27.06.2009 Russian Federation, proposed a method of producing microcapsules of sodium chloride with the use of spray cooling in the spray tower Niro under the following conditions: air temperature at the inlet 10°C, the temperature at the outlet 28°C, the speed of rotation of the spray drum 10000 rpm/min Microcapsules according to the invention have improved stability and ensure the up regulated and/or prolonged release of the active ingredient.

Disadvantages of the proposed method are the duration of the process and the use of special equipment, a set of conditions (temperature of inlet air 10°C, the temperature at the outlet 28°C, the speed of rotation of the spray drum 10000 rpm).

The closest method is the method proposed in U.S. Pat. 2134967, IPC A01N 53/00, A01N 25/28 published 27.08.1999 Russian Federation (1999). Water is dispersed solution of a mixture of natural lipids and a PYRETHROID insecticide in the weight ratio of 2-4: 1 in an organic solvent, which leads to simplification of the method of microencapsulation.

The disadvantage of this method is the dispersion in the aquatic environment, which makes the proposed method applicable to the production of microcapsules of water-soluble drugs in water-soluble polymers.

The technical objective is the simplification and acceleration of the process of production of microcapsules, the reduction of losses upon receipt of the microcapsules (increase in mass).

The solution of the technical problem is achieved by a method of producing particles encapsulated activator-promoter Dorogov (DCA) 2 fraction, characterized in that as the shell of the microcapsules used sodium alginate, as well as kernel - SDA 2 faction when receiving the encapsulated particles by precipitation with nerastvorim using tetrachloride ug is erode as precipitator, the process of production of microcapsules is carried out without special equipment.

A distinctive feature of the proposed method is to obtain microcapsules by precipitation with nerastvorim using carbon tetrachloride as a precipitator, and the use of sodium alginate as the shell particles and the SDA 2 fraction as a kernel.

The result of the proposed method are obtaining microcapsules SDA 2 fraction in the shell of the sodium alginate.

SDA 2 fraction is a fabric preparation of animal origin. Comprises: connection active sulfhydryl group, derivatives of aliphatic amines, carboxylic acids, aliphatic and cyclic hydrocarbons, derivatives of amides and water. The SDA-2 in oral application has an activating effect on the Central nervous system and autonomic nervous system, stimulates motor activity of the gastrointestinal tract, the secretion of digestive glands, increases the activity of the digestive and tissue enzymes, improves the penetration of the ions Na+ and K+ across cell membranes, helps normalize digestion, absorption of nutrients and increase the natural resistance of the organism. When applied externally, the drug stimulates the activity of the reticuloendothelial system,normalizes the trophic and accelerates regeneration of damaged tissues, has a strong antiseptic and anti-inflammatory action.

EXAMPLE 1. Obtaining microcapsules SDA 2 faction in the sodium alginate, the ratio of core:shell 1:3

100 mg SDA 2 fraction was dispersed in a suspension of sodium alginate in isopropanol containing specified 300 mg of the polymer in the presence of 0.01 g of the drug Is (ester of glycerol with one or two molecules of dietary fatty acids and one or two molecules of citric acid, and citric acid as Tihonova can be etherification other glycerides and as oxanilate - other fatty acids. Free acid groups can be neutralized with sodium) under stirring 1300 R/C. Then poured 5 ml of carbon tetrachloride. The precipitation is filtered off and dried at room temperature.

Obtained 0.4 g of powder of microcapsules. The yield was 100%.

EXAMPLE 2. Obtaining microcapsules SDA 2 faction in the sodium alginate, the ratio of core:shell 1:1

100 mg SDA 2 fraction was dispersed in a suspension of sodium alginate in isopropanol containing specified 100 mg of the polymer in the presence of 0.01 g of the drug Is (ester of glycerol with one or two molecules of dietary fatty acids and one or two molecules of citric acid, and citric acid as Tihonova can be etherification other glycerides and exocyclic is - other fatty acids. Free acid groups can be neutralized with sodium) under stirring 1300 R/C. Then poured 5 ml of carbon tetrachloride. The precipitation is filtered off and dried at room temperature.

Obtained 0.2 g of powder of microcapsules. The yield was 100%.

The method of producing encapsulated particles of antiseptic, stimulant Dorogov (DCA)2 fraction, characterized in that the shell uses sodium alginate, which precipitated from solution in isopropanol in the presence of ester of glycerol with one or two molecules of dietary fatty acids and one or two molecules of citric acid by adding as a precipitator of carbon tetrachloride and drying of the particles is carried out at room temperature.



 

Same patents:

FIELD: chemistry.

SUBSTANCE: method of encapsulating creatine is a physical-chemical non-solvent deposition method. The envelope used is sodium alginate, which is deposited from a solution in butanol in the presence of a glycerol ester with one or two molecules of edible fatty acids and one or two molecules of citric acid by adding chloroform as a precipitant.

EFFECT: simple and faster process of producing microcapsules and higher mass output.

3 dwg, 3 ex

FIELD: chemistry.

SUBSTANCE: distinctive feature of the present method is the use of betaine as an antioxidant and sodium alginate as a microcapsule envelope, as well as the use of tetrachloromethane as a precipitant when producing microcapsules using a physical-chemical non-solvent deposition method.

EFFECT: simple and faster process of producing microcapsules and higher mass output.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the chemical-pharmaceutical industry and represents a method for a drug encapsulation by a non-solvent addition, differing by the fact that the drug is fenbendazole, and a coating is sodium carboxymethyl cellulose deposited from a heptane solution by adding methylcarbinol as the non-solvent and water at 25 °C.

EFFECT: invention provides simplifying and accelerating the process of preparing microcapsules, reducing the accompanying loss (higher weight yield).

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a method for drug encapsulation by non-solvent addition, differing by the fact that the drug is presented by fenbendazole, while the coating is sodium carboxymethyl cellulose, which is deposited from the solution in butanol by adding carbinol as a non-solvent and water at 25°C.

EFFECT: invention provides simplifying and accelerating the process of microcapsules, reducing production loss (high mass yield).

3 ex

FIELD: chemistry.

SUBSTANCE: invention represents method of obtaining microcapsules of medications by method of precipitation with non-solvent, characterised by the fact that preparations of cephalosporine group are used as medications, α- and β-forms of human leukocyte interferon, precipitated from water solution by addition as non-solvent methylcarbinol and acetone at 25°C, are used as envelope.

EFFECT: simplification and acceleration of obtaining microcapsules, reduction of loss in the process of obtaining microcapsules, increase of output by weight.

4 ex

FIELD: chemistry.

SUBSTANCE: invention represents method of medication encapsulation by method of precipitation with non-solvent, characterised by the fact that fenbendazole is used as medication, sodium carboxymethylcellulose, precipitated from solution in carbon tetrachloride by addition a non-solvent butanol and water at 25°C, is used as envelope.

EFFECT: simplification and acceleration of the process of obtaining microcapsules, reduction of loss in the process of microcapsule obtaining, increase of output by weight.

3 ex

FIELD: chemistry.

SUBSTANCE: invention represents method of medication encapsulation by method of precipitation with non-solvent, characterised by the fact that fenbendazole is used as medication, sodium carboxymethylcellulose, precipitated from solution in dichloromethane by addition as non-solvent of methylcarbinol and water at 25°C, is used as envelope.

EFFECT: simplification and acceleration of the process of obtaining microcapsules, reduction of loss in the process of microcapsule obtaining, increase of output by weight.

3 ex

FIELD: chemistry.

SUBSTANCE: invention represents method of obtaining microcapsules of medication by method of precipitation with non-solvent, characterised by the fact that Sel-Plex is used as medication, and xanthan gum, precipitated from solution in butanol by addition as non-solvent of toluene and water, is used as envelope.

EFFECT: simplification and acceleration of obtaining microcapsules, reduction of loss in the process of obtaining microcapsules, increase of output by weight.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a method for drug encapsulation by non-solvent addition, differing by the fact that the drug is presented by fenbendazole, while the coating is sodium carboxymethyl cellulose, which is deposited from the solution in chloroform by adding butanol as a non-solvent and water at 25°C.

EFFECT: invention provides simplifying and accelerating the process of microcapsules, reducing production loss (high mass yield).

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a method for producing drug microcapsules by non-solvent addition, differing by the fact that the drugs are presented by cephalosporin preparations, while the coating is human leukocyte interferon α and β, which is deposited from an aqueous solution by adding isopropanole as a non-solvent and acetone at 25°C.

EFFECT: invention provides simplifying and accelerating the process of microcapsules, reducing production loss (higher mass yield).

4 ex

FIELD: chemistry.

SUBSTANCE: method of encapsulating creatine is a physical-chemical non-solvent deposition method. The envelope used is sodium alginate, which is deposited from a solution in butanol in the presence of a glycerol ester with one or two molecules of edible fatty acids and one or two molecules of citric acid by adding chloroform as a precipitant.

EFFECT: simple and faster process of producing microcapsules and higher mass output.

3 dwg, 3 ex

FIELD: chemistry.

SUBSTANCE: distinctive feature of the present method is the use of betaine as an antioxidant and sodium alginate as a microcapsule envelope, as well as the use of tetrachloromethane as a precipitant when producing microcapsules using a physical-chemical non-solvent deposition method.

EFFECT: simple and faster process of producing microcapsules and higher mass output.

2 ex

FIELD: chemistry.

SUBSTANCE: described is method of obtaining particles of encapsulated with fat-soluble polymer envelope flavour enhancer, which possess supramolecular properties, with fat-soluble polymer being used as microcapsule envelope and flavour enhancer "gooseberry" being used as core in production of encapsulated particles by method of precipitation with non-solvent with application of acetone and butanol as precipitators.

EFFECT: simplification and acceleration of the process of producing microcapsules, reduction of loss in production of microcapsules.

1 dwg, 2 ex

FIELD: chemistry.

SUBSTANCE: method represents physico-chemical of precipitation with non-solvent, in which as microcapsule envelope xanthan gum, as core - ADS 2 fraction, and as precipitating agent - benzene are used.

EFFECT: simplification and acceleration of the process of obtaining microcapsules and increase of output by their weight.

3 dwg, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and represents an oral pharmaceutical composition for treating intestinal disorders, containing butyric acid or its salt in a combination with water-soluble or water-dispersed dietary fibre specified in inulin, maltodextrin or a mixture thereof, at least one flavouring agent specified in vanillin, vanilla essence or a mixture thereof and one or more pharmacologically acceptable excipients differing by the fact that it contains: a) a matrix containing lipophilic compounds with a melting point of less than 90°C, and an amphiphilic matrix wherein an active ingredient is at least ball-shaped; b) an amphiphilic matrix; c) an outer hydrophilic matrix wherein the lipophilic matrix and the amphiphilic matrix are dispersed; e) a coating; and a portion of the above at least one flavouring agent is dispersed in one or more of the above matrixes, and a portion of the flavouring agent is dispersed in the coating.

EFFECT: preparing the pharmaceutical composition for treating intestinal disorders.

22 cl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is a group of inventions involving a pharmaceutical composition, a method of preparing it, a method of treating Parkinson's disease and a method of reducing a 'wear' effect in the given patients by administering the same. The pharmaceutical composition in the form of a single oral dose for treating Parkinson's disease consists of a mixture of a) Levodopa or its salt in an amount of 50 mg to 300 mg in the form of prolonged release, b) Carbidopa or its salt in an amount of 10 mg to 100 mg in the form of prolonged release, wherein the prolonged release is ensured by coating or mixing Levodopa and Carbidopa with one or more rate control polymers, and c) Entacapone or its salt in an amount of 100 mg to 1000 mg in the form of prolonged release, optionally with other pharmaceutically acceptable excipients.

EFFECT: group of inventions promotes patient's treatment compliance; using it leads to a stable blood content of active antigens and to reducing administration rate that provides reducing the 'wear' effect in the patients with Parkinson's disease; besides, the additional technical effect ensured by the composition consists in its stability at high temperature and humidity.

9 cl, 15 tbl

FIELD: medicine.

SUBSTANCE: invention refers to using a polyurethane polymer as a drug delivery system to provide the biologically active risperidone delivery at a constant speed for a relatively long period of time, as well as to methods for using it.

EFFECT: system provides high biological compatibility and biological stability and is applicable as an implant in patients (humans and animals) for the risperidone delivery to tissues and organs.

25 cl, 13 dwg, 3 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: group concerns a prolonged delivery of a compstatin analogue, as well as an optional additional active agent when released from a microscopic gel-like inclusion formed if a liquid composition containing the compstatin analogue is introduced into an extravascular space, such as a vitreous chamber of eye in a mammalian body. The invention also refers to a method of treating an individual suffering age-related macular degeneration (ARMD).

EFFECT: improving the compstatin delivery system for the complement system inhibition required for treating ARMD.

58 cl, 4 ex, 6 tbl, 5 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical compositions containing (2-hydroxyethoxy)amide 6-(4-brom-2-chlorophenylamino)-7-fluor-3-methyl-3H-benzoimidazole-5-carboxylic acid hydrosulphate and solvates, crystalline forms and amorphous forms thereof, to using the above compositions as a drug; and to methods for preparing the above compositions.

EFFECT: preparing the new pharmaceutical compositions.

20 cl, 7 tbl, 7 ex, 5 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a pharmaceutical composition for outpatient treatment and prevention of the cardiovascular diseases, containing therapeutic amounts of a vasodilator, a renin-angiotensin system inhibitor, a thrombocyte aggregation inhibitor, a cholesterol-lowering agent, and an antihypoxic agent. As a vasodilator, the declared composition contains an agent possessing α-adrenergic receptor antagonist action, and a thrombocyte aggregation inhibitor is presented by an ADP-dependent thrombocyte activation mechanism blocking agent.

EFFECT: invention provides the integrated therapeutic effect on the cardiovascular system after acute administration that improves the compliance with treatment regimen by the patient.

20 cl, 1 tbl, 15 ex

FIELD: chemistry.

SUBSTANCE: method of encapsulating creatine is a physical-chemical non-solvent deposition method. The envelope used is sodium alginate, which is deposited from a solution in butanol in the presence of a glycerol ester with one or two molecules of edible fatty acids and one or two molecules of citric acid by adding chloroform as a precipitant.

EFFECT: simple and faster process of producing microcapsules and higher mass output.

3 dwg, 3 ex

Up!